Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer

NCT04269200 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

805

Enrollment

INDUSTRY

Sponsor class

Conditions

Endometrial Neoplasms

Interventions

DRUG: olaparib
BIOLOGICAL: durvalumab
DRUG: durvalumab placebo
DRUG: olaparib placebo
DRUG: Carboplatin
DRUG: Paclitaxel

Sponsor

AstraZeneca

Collaborators

[object Object]
[object Object]